Teva Pharmaceutical Industries (NYSE:TEVA) Announces Earnings Results, Misses Estimates By $0.06 EPS

Teva Pharmaceutical Industries (NYSE:TEVA) announced its quarterly earnings results on Wednesday. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.06), FiscalAI reports. The business had revenue of $4.14 billion for the quarter, compared to analyst estimates of $4.02 billion. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.Teva Pharmaceutical Industries’s quarterly revenue was down .8% compared to the same quarter last year. During the same period last year, the firm earned $0.66 EPS. Teva Pharmaceutical Industries updated its FY 2026 guidance to 1.910-2.110 EPS.

Here are the key takeaways from Teva Pharmaceutical Industries’ conference call:

• Innovative products drove growth: AUSTEDO, UZEDY, and AJOVY delivered strong Q2 increases, prompting Teva to raise their combined 2026 revenue outlook by approximately $150 million at the midpoint. AUSTEDO revenue rose 40% globally, UZEDY 43%, and AJOVY 56% year over year.
• Teva raised its full-year 2026 revenue guidance midpoint by $75 million and reported $622 million of free cash flow, up 31% year over year. Management reaffirmed its targets of a 30% non-GAAP operating margin, net debt/EBITDA below 2x, and 80% cash conversion by 2027.
• The development pipeline is advancing, with potential submissions or launches including olanzapine LAI in late 2026, ecopipam for Tourette syndrome in 2027, and additional programs through 2030. Teva also expanded duvakitug development into hidradenitis suppurativa and fibrostenotic Crohn’s disease, while anti-IL-15 programs remain active in vitiligo and celiac disease.
• Generics revenue declined 15% year over year, primarily because of lower generic REVLIMID contributions, although management said the underlying generics business was broadly stable and biosimilars are becoming a growth platform. Teva expects biosimilar revenue to exceed its $800 million 2027 target.
• Management expects elevated AUSTEDO channel inventory to normalize over the next two quarters and warned that Q4 AUSTEDO revenue could decline year over year amid purchasing and pricing changes ahead of IRA implementation. Higher planned operating expenses, unfavorable foreign exchange, and the $724 million Emalex acquisition-related R&D charge also pressured reported profitability.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded up $0.02 during mid-day trading on Thursday, hitting $34.73. 2,269,000 shares of the company’s stock were exchanged, compared to its average volume of 7,275,235. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries has a 52 week low of $14.99 and a 52 week high of $37.35. The stock’s 50-day simple moving average is $33.19 and its 200-day simple moving average is $32.69. The firm has a market cap of $39.93 billion, a price-to-earnings ratio of 26.01, a price-to-earnings-growth ratio of 3.35 and a beta of 0.86.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Higher revenue outlook: Teva raised its 2026 revenue guidance to $16.5 billion–$16.9 billion, with the midpoint increasing by $75 million and broadly in line with analyst expectations. Teva outlines higher 2026 revenue guidance
• Positive Sentiment: Innovative medicines gaining momentum: Teva’s key branded products grew 43% year over year in local-currency terms to more than $1 billion in quarterly revenue. AUSTEDO, AJOVY and UZEDY all received higher full-year outlooks, supporting management’s strategy of reducing reliance on lower-growth generics. Teva delivers strong Q2 results and raises outlook
• Positive Sentiment: UZEDY sales accelerated: The long-acting schizophrenia treatment generated record second-quarter U.S. sales of $77 million, up 43% year over year. Teva lifted its 2026 UZEDY revenue forecast to $270 million–$290 million. UZEDY record sales and higher outlook
• Positive Sentiment: Analyst and options support: Piper Sandler raised its price target to $44 from $42 and maintained an overweight rating. Call-option activity was also unusually high, indicating increased speculative bullish interest. Piper Sandler price target
• Neutral Sentiment: Mixed quarterly results: Second-quarter revenue of $4.14 billion exceeded estimates of $4.02 billion but declined about 1% year over year. Teva reported adjusted EPS of $0.02, below the $0.08 consensus, while the company’s reported net loss reached $576 million because of impairment and acquisition-related charges. Teva second-quarter earnings report
• Negative Sentiment: Profit outlook remains pressured: Teva’s 2026 EPS guidance of $1.91–$2.11 is below the $2.17 analyst consensus, and ongoing impairments and declining generics sales remain risks to the branded-drug transition.

Analysts Set New Price Targets

Several research analysts have recently commented on TEVA shares. Bank of America lifted their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Barclays increased their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Piper Sandler upped their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Truist Financial increased their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $42.00.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the transaction, the executive vice president owned 65,621 shares in the company, valued at $2,237,676.10. This trade represents a 61.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Amir Weiss sold 10,679 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the transaction, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at $720,576. This represents a 34.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 444,673 shares of company stock worth $15,582,369. 0.54% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Large investors have recently bought and sold shares of the company. Global Retirement Partners LLC raised its position in shares of Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after buying an additional 292 shares in the last quarter. Captrust Financial Advisors boosted its position in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock worth $459,000 after acquiring an additional 302 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in Teva Pharmaceutical Industries by 1.2% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 36,921 shares of the company’s stock valued at $1,152,000 after acquiring an additional 449 shares during the last quarter. CIBC Private Wealth Group LLC increased its stake in Teva Pharmaceutical Industries by 15.5% in the third quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock valued at $81,000 after acquiring an additional 540 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in Teva Pharmaceutical Industries by 0.5% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 118,209 shares of the company’s stock valued at $1,981,000 after purchasing an additional 615 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.